Clinical Study on the Effectiveness and Safety of Guanxinning Tablets on Coronary Heart Disease Complicated with Diabetic Nephropathy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054422

Enrollment

Unknown

Registered

2021-12-17

Start date

2021-12-20

Completion date

Unknown

Last updated

2022-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease combined with diabetic nephropathy

Interventions

Control group:Conventional treatment

Experimental group:Conventional treatment + Guanxinning tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for blood stasis syndrome of coronary heart disease ("Diagnostic criteria for blood stasis syndrome of coronary heart disease"); 2. Meet the diagnostic criteria for diabetes mellitus (DM) established by the ADA in 2020; 3. Those who meet one of the following conditions ("Chinese Guidelines for Clinical Diagnosis and Treatment of Diabetic Kidney Diseases 2021"): (1) One of the cases of random urinary albumin/creatinine ratio (UACR) >= CR or urinary albumin excretion rate (UAER) >= >= >= R white excretion rate; (2) Estimated glomerular filtration rate (eGFR) = 18 years; 5. Subjects were informed and signed the informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. Infection, fever, congestive heart failure, uncontrolled blood sugar, blood pressure, urinary tract infection; 2. Unwilling to cooperate and mentally ill; 3. Combined with serious diseases such as heart, lung, brain, liver, kidney, hematopoietic system; 4. ALT and AST are higher than 3 times the upper limit of the normal range; 5. Patients who have participated in clinical trials of other drugs in the past 1 month; 6. Pregnant or planning to become pregnant, lactating women; 7. Those who have a history of drug allergy or allergic constitution and are allergic to multiple drugs; 9. Other patients who do not meet the inclusion criteria as judged by the investigator.

Design outcomes

Primary

Measure	Time frame
24-hour urine protein quantification;Estimated glomerular filtration rate;Urine albumin/creatinine ratio;	—

Secondary

Measure	Time frame
Glycated hemoglobin;Changes in inflammation levels;Blood lipids;Fasting blood glucose;	—

Countries

China

Contacts

Public ContactXu Zhao

The Affiliated Hospital of Hangzhou Normal University

13735527510@163.com+86 13735527510

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026